ImmunityBio shares rose over 5% pre-market after a volatile session tied to its Phase 2 glioblastoma update. Founder Patrick Soon-Shiong clarified survival metrics, noting median survival has not yet been reached. Retail sentiment remained supportive as patient enrolment continues.
Sponsored Advertisement
No comments yet. Be the first!